Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Basic): 2014-2024

Historic EPS (Basic) for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$4.48.

  • Cartesian Therapeutics' EPS (Basic) fell 22.12% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.42, marking a year-over-year increase of 97.30%. This contributed to the annual value of -$4.48 for FY2024, which is 91.00% up from last year.
  • Cartesian Therapeutics' EPS (Basic) amounted to -$4.48 in FY2024, which was up 91.00% from -$49.76 recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' EPS (Basic) registered a high of $0.24 during FY2022, and its lowest value of -$49.76 during FY2023.
  • For the 3-year period, Cartesian Therapeutics' EPS (Basic) averaged around -$18, with its median value being -$4.48 (2024).
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 209.09% in 2022, then plummeted by 20,833.33% in 2023.
  • Cartesian Therapeutics' EPS (Basic) (Yearly) stood at -$0.68 in 2020, then soared by 67.65% to -$0.22 in 2021, then skyrocketed by 209.09% to $0.24 in 2022, then crashed by 20,833.33% to -$49.76 in 2023, then surged by 91.00% to -$4.48 in 2024.